Therapeutic and prophylactic applications of alphavirus vectors

Expert Reviews in Molecular Medicine

Volumn 10, Issue 33, 2008, Pages 1-18

  Atkins, Gregory J ^a   Fleeton, Marina N ^a   Sheahan, Brian J ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA VIRUS VACCINE; ALPHA VIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; CANCER VACCINE; COMPLEMENTARY DNA; DNA; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; MUC 18 VACCINE; ONCOLYTIC VIRUS; RNA; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VIRUS VACCINE; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ARTICLE; BIOSAFETY; BREAST CANCER; CANCER INHIBITION; CARCINOMA; CENTRAL NERVOUS SYSTEM; CYTOMEGALOVIRUS; CYTOPLASM; DRUG EFFICACY; EXPRESSION VECTOR; GENE AMPLIFICATION; GENOME; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA; MULTIPLE SCLEROSIS; NONHUMAN; PAPILLOMA VIRUS; PATHOGENICITY; PRIORITY JOURNAL; PROMOTER REGION; PROPHYLAXIS; PROSTATE CANCER; REPLICON; SEMLIKI FOREST ALPHAVIRUS; SINDBIS VIRUS; TRANSGENE; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VERTEBRATE; VIRUS PARTICLE; WILD TYPE;

ALPHAVIRUS; CYTOMEGALOVIRUS; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VERTEBRATA;

EID: 56349136379     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399408000859     Document Type: Article

References (113)

1. Strauss, J.H. and Strauss, E.G. (1994) The alphaviruses: Gene expression, replication and evolution. Microbiol Rev 58, 491-562
2. Liljestrom, P. and Garoff, H. (1991) A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 9, 1356-136
3. Smithburn, K.C. and Haddow, A.J. (1944) Semliki Forest virus. I. Isolation and pathogenic properties. J Immunol 49, 141-157
4. Mathiot, C.C. et al. (1990) An outbreak of human Semliki Forest virus infection in Central African Republic. Am J Trop Med Hyg 42, 386-393
5. Willems, W.R. et al. (1979) Semliki Forest virus: Cause of a fatal case of human encephalitis. Science 203, 1127-1129
6. HHS Publication (1999) Biosafety in Microbiological and Biomedical Laboratories (4th edn), US Government Priniting Office, Washington, USA
7. E.C. Council Directive 93/88/EEC (1993) The protection of workers from risks related to exposure to biological agents at work. Official Journal of the European Communities 268, 71-82
8. Laine, M., Luukkainen, R. and Toivanen, A. (2004) Sindbis viruses and other alphaviruses as cause of human arthritic disease. J Intern Med 256, 457-471
9. Polo, J.M. et al. (1988) Molecular analysis of Sindbis virus pathogenesis in neonatal mice by using virus recombinants constructed in vitro. J Virol 62, 2124-2133
10. Pushko, P. et al. (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239, 389-401
11. Atkins, G.J., Sheahan, B.J. and Liljeström, P. (1999) The molecular pathogenesis of Semliki Forest virus: A model virus made useful? J Gen Virol 80, 2287-2297
12. Bradish, C.J., Allner, K. and Maber, H.B. (1972) Infection, interaction and the expression of virulence by defined strains of Semliki forest virus. J Gen Virol 16, 359-372
13. Smerdou, C. and Liljeström, P. (1999) Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 73, 1092-1098
14. Berglund, P. et al. (1998) Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16, 562-565
15. Ljungberg, K. et al. (2007) Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol 81, 13412-13423
16. Tamang, D. et al. (2004) The use of a double subgenomic Sindbis virus expression system to study mosquito gene function: Effects of antisense nucleotide number and duration of viral infection on gene silencing efficiency. Insect Mol Biol 13, 595-602
17. Galbraith, S.E., Sheahan, B.J. and Atkins, G.J. (2006) Deletions in the hypervariable domain of the nsP3 gene attenuate Semliki Forest virus virulence. J Gen Virol 87, 937-947
18. Casales, E. et al. (2008) Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability.
19. Lundstrom, K. et al. (2003) Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol Ther 7, 202-209
20. Vähä-Koskela, M.J. et al. (2003) A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 9, 1-15
21. Vähä-Koskela, M.J., Heikkilä, J.E. and Hinkkanen, A.E. (2007) Oncolytic viruses in cancer therapy Cancer Lett 254, 178-216
22. Morris-Downes, M.M. et al. (2001) Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19, 1978-1988
23. Riezebos-Brilman, A. et al. (2007) A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther 14, 1695-1704
24. Fleeton, M.N. et al. (2001) Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183, 1395-1398
25. Riezebos-Brilman, A. et al. (2006) Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol 35, 233-243
26. Lundstrom, K. (2003) Alphavirus vectors for vaccine production and gene therapy Expert Rev Vaccines 2, 447-459
27. Bredenbeek, P.J. et al. (1993) Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67, 6439-6446
28. Perri, S. et al. (2003) An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77, 10394-10403
29. Vajdy, M. et al. (2001) Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunization with sindbis virus-based replicon particles. J Infect Dis 184, 1613-1616
30. Dong, M. et al. (2003) Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small mammals by using an alphavirus-derived in vivo expression system. J Virol 77, 3119-3130
31. Hanke, T. et al. (2003) Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84, 361-368
32. Sundback, M. et al. (2005) Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 341, 190-202
33. Forsell, M.N. et al. (2007) Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector. J Gen Virol 88, 2774-2779
34. Forsell, M.N. et al. (2005) Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol 79, 10902-10914
35. Davis, N.I. et al. (2000) Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 74, 371-378
36. Nilsson, C. et al. (2001) Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19, 3526-3536
37. Johnston, R.E. et al. (2005) Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 23, 4969-4979
38. Xu, R. et al. (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIV Gag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22, 1022-1030
39. Ehrengruber, M.U. et al. (2003) Semliki Forest virus A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner. J Neurovirol 9, 16-28
40. Graham, A. et al. (2006) CNS gene therapy applications of the Semliki Forest virus vector are limited by neurotoxicity. Mol Ther 13, 631-635
41. Sammin, D.J. et al. (1999) Cell death mechanisms in the olfactory bulb of rats infected intranasally with Semliki forest virus. Neuropathol Appl Neurobiol 25, 236-243
42. Jerusalmi, A. et al. (2003) Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 8, 886-894
43. Quinn, K. et al. (2008) Effect of intranasal administration of Semliki Forest virus recombinant particles expressing interferon-β on the progression of experimental autoimmune encephalomyelitis. Mol Med Rep 1, 335-342
44. Vähä-Koskela, M.J. et al. (2007) Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice. Biochem Biophys Res Commun 355, 776-781
45. Nygårdas, P.T. et al. (2004) Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2. Scand J Immunol 60, 372-381
46. Kelly, B.J., Fleeton, M.N. and Atkins, G.J. (2007) Potential of alphavirus vectors in the treatment of advanced solid tumors. Recent Patents Anticancer Drug Discov 2,159-166
47. Atkins, G.J. et al. (2004) Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4, 597-607
48. Yamanaka, R. (2004) Alphavirus vectors for cancer gene therapy. Int J Oncol 24, 919-923
49. Lundstrom, K. (2002) Alphavirus vectors as tools in cancer gene therapy. Technol Cancer Res Treat 1, 83-88
50. Velders, M.P. et al. (2001) Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61, 7861-7867
51. Daemen, T. et al. (2003) Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21, 1082-1088
52. Cheng, W.F. et al. (2006) Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther 13, 873-885
53. Cassetti, M.C. et al. (2004) Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22, 520-527
54. Riezebos-Brilman, A. et al. (2005) Induction of human papillomavirus E6/ E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7 transgenic mice. Gene Ther 12, 1410-1414
55. Laust, A.K. et al. (2007) VIP immunotherapy targeting neu: Treatment efficacy and evidence for immunoediting in a stringent rat mammary tumour model. Breast Cancer Res Treat 106, 371-382
56. Wang, X. et al. (2005) Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res 7, 145-155
57. Leslie, M.C. et al. (2007) Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastsis. Gene Ther 14, 316-323
58. Vähä-Koskela, M.J. et al. (2006) Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 66, 7185-7194
59. Wollmann, G., Tattersall, P. and van den Pol, A.N. (2005) Targeting human glioblastoma cells: Comparison of nine viruses with oncolytic potential. J Virol 79, 6005-6022
60. Zhang, J., Frolov, I. and Russell, S.J. (2004) Gene therapy for malignant glioma using Sindbis vectors expressinga fusogenic membrane glycoprotein. J Gene Med 6, 1082-1091
61. Lee, J.S. et al. (2006) Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells. Int J Oncol 28, 649-654
62. Maatta, A.M. et al. (2007) Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 121, 863-870
63. Garcia-Hernandez Mde, L. et al. (2007) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: A candidate antigen for treating prostate cancer. Cancer Res 67, 1344-1351
64. Garcia-Hernandez, M. de la L. et al. (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68, 861-869
65. Durso, R.J. et al. (2007) A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 13, 3999-4008
66. Tseng, J.C. et al. (2007) Restricted tissue tropism and acquired resistance to Sindbis viral vector expression in the absence of innate and adaptive immunity. Gene Ther 14, 1166-1174
67. Hurtado, A. et al. (2005) Identification of amino acids of Sindbis virus E2 protein involved in targeting tumor metastases in vivo. Mol Ther 12, 813-823
68. Tseng, J.C. et al. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 64, 6684-6692
69. Tseng, J.C. et al. (2004) Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22, 70-77
70. Rodriguez-Madoz, J.R., Ptrieto, J. and Smerdou, C. (2007) Biodistribution and tumor infectivity of semliki forest virus vectors in mice: Effects of readministration. Mol Ther 15, 2164-2171
71. Murphy, A.M. et al. (2000) Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther 17, 1477-1482
72. Murphy, A.M, Sheahan, B.J. and Atkins, G.J. (2001) Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector. Int J Cancer 94, 572-578
73. Smyth, J.W. et al. (2005) Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther 12, 147-159
74. Chikkanna-Gowda, C.P. et al. (2006) Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18. Oncol Rep 16, 713-719
75. Chikkanna-Gowda, C.P. et al. (2005) Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12, 1253-1263
76. Rodriguez-Madoz, J.R., Prieto, J. and Smerdou, C. (2005) Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 12, 153-163
77. Lyons, J.A. (2007) Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther 14, 503-513
78. Hubby, B. et al. (2007) Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25, 8180-8189
79. Villa, I.I. et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95, 1459-1466
80. Kistner, O. et al. (2007) The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25, 4845-4852
81. Ren, H. et al. (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol 64, 147-254
82. Pugachev, K.V. et al. (1995) Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212, 587-594
83. Seo, S.H. et al. (1977) The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol 71, 7889-7894
84. Hariharan, M.J. et al. (1998) DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector. J Virol 72, 950-958
85. Reddy, J.R. et al. (1999) Semliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells. Comp Immunol Microbiol Infect Dis 22, 231-246
86. Morris-Downes, M.M. et al. (2001) A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine 19, 3877-3884
87. Fleeton, M.N. et al. (2000) Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 81, 749-758
88. Fleeton, M.N. et al. (1999) Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 80, 1189-1198
89. Berglund, P. et al. (1999) Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17, 497-507
90. Schultz-Cherry, S. et al. (2000) Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59
91. Tsuji, M. et al. (1998) Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 72, 6907-6910
92. Hevey, M. et al. (1998) Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251, 28-37
93. Colombage, G. et al. (1998) DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163
94. Kamrud, K.I. et al. (1999) Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 266, 209-219
95. Pushko, P. et al. (2000) Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19, 142-153
96. Pushko, P. et al. (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75, 11677-11685
97. Balasuriya, U.B. et al. (2002) Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20, 1609-1617
98. Balasuriya, U.B. et al. (2000) Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J Virol 74, 10623-10630
99. Chen, M. et al. (2002) Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169, 3208-3216
100. Elliott, M.B. et al. (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144
101. Harrington, P.R. et al. (2002) Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 76, 730-742
102. Burkhard, M.J. et al. (2002) Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats. Vaccine 21, 258-268
103. Dory, D. et al. (2006) Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus. Vaccine 24, 6256-6263
104. Li, N. et al. (2007) A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge. Vaccine 25, 2907-2912
105. Thornburg, N.J. et al. (2007) Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology 362, 441-452
106. Reap, E.A. et al. (2007) Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 14, 748-755
107. Callagy, S.J. et al. (2007) Semliki Forest virus vectors expressing the H and HN genes of measles and mumps viruses reduce immunity induced by the envelope protein genes of rubella virus. Vaccine 25, 7481-7490
108. Pan, C.H. et al. (2005) Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 102, 11581-11588
109. Pasetti, M.F. et al. (2007) Heterologous primeboost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques. Clin Pharmacol Ther 82, 672-685
110. Lee, J.S. et al. (2002) Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J Infect Dis 185, 1192-1196
111. Lee, J.S. et al. (2006) Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 24, 6886-6892
112. Oñate, A.A. et al. (2005) An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 73, 3294-3300
113. Derrick, S.C., Yang, A.L. and Morris, S.L. (2005) Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis. Infect Immun 73, 7727-7735